Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Long-term use of continuous-combined estrogen-progestin hormone therapy and risk of endometrial cancer.

Phipps AI, Doherty JA, Voigt LF, Hill DA, Beresford SA, Rossing MA, Chen C, Weiss NS.

Cancer Causes Control. 2011 Dec;22(12):1639-46. doi: 10.1007/s10552-011-9840-6. Epub 2011 Sep 11.

2.

Pregnancy history and risk of endometrial cancer.

Pocobelli G, Doherty JA, Voigt LF, Beresford SA, Hill DA, Chen C, Rossing MA, Holmes RS, Noor ZS, Weiss NS.

Epidemiology. 2011 Sep;22(5):638-45. doi: 10.1097/EDE.0b013e3182263018.

3.

Feasibility of including cellular telephone numbers in random digit dialing for epidemiologic case-control studies.

Voigt LF, Schwartz SM, Doody DR, Lee SC, Li CI.

Am J Epidemiol. 2011 Jan 1;173(1):118-26. doi: 10.1093/aje/kwq322. Epub 2010 Nov 11.

4.

Complex hyperplasia with and without atypia: clinical outcomes and implications of progestin therapy.

Reed SD, Newton KM, Garcia RL, Allison KH, Voigt LF, Jordan CD, Epplein M, Swisher E, Upson K, Ehrlich KJ, Weiss NS.

Obstet Gynecol. 2010 Aug;116(2 Pt 1):365-73. doi: 10.1097/AOG.0b013e3181e93330.

5.

Infertility treatment use in relation to selected adverse birth outcomes.

Welmerink DB, Voigt LF, Daling JR, Mueller BA.

Fertil Steril. 2010 Dec;94(7):2580-6. doi: 10.1016/j.fertnstert.2010.03.005.

PMID:
20434152
6.

Does pregnancy provide vaccine-like protection against rheumatoid arthritis?

Guthrie KA, Dugowson CE, Voigt LF, Koepsell TD, Nelson JL.

Arthritis Rheum. 2010 Jul;62(7):1842-8. doi: 10.1002/art.27459.

7.

Is the incidence of invasive vulvar cancer increasing in the United States?

Bodelon C, Madeleine MM, Voigt LF, Weiss NS.

Cancer Causes Control. 2009 Nov;20(9):1779-82. doi: 10.1007/s10552-009-9418-8. Epub 2009 Aug 13.

8.

Incidence of endometrial hyperplasia.

Reed SD, Newton KM, Clinton WL, Epplein M, Garcia R, Allison K, Voigt LF, Weiss NS.

Am J Obstet Gynecol. 2009 Jun;200(6):678.e1-6. doi: 10.1016/j.ajog.2009.02.032. Epub 2009 Apr 23.

9.

Progestin therapy of complex endometrial hyperplasia with and without atypia.

Reed SD, Voigt LF, Newton KM, Garcia RH, Allison HK, Epplein M, Jordan D, Swisher E, Weiss NS.

Obstet Gynecol. 2009 Mar;113(3):655-62. doi: 10.1097/AOG.0b013e318198a10a.

10.

Endometrial hyperplasia risk in relation to recent use of oral contraceptives and hormone therapy.

Epplein M, Reed SD, Voigt LF, Newton KM, Holt VL, Weiss NS.

Ann Epidemiol. 2009 Jan;19(1):1-7. doi: 10.1016/j.annepidem.2008.08.099.

11.

Risk of complex and atypical endometrial hyperplasia in relation to anthropometric measures and reproductive history.

Epplein M, Reed SD, Voigt LF, Newton KM, Holt VL, Weiss NS.

Am J Epidemiol. 2008 Sep 15;168(6):563-70; discussion 571-6. doi: 10.1093/aje/kwn168. Epub 2008 Aug 5.

12.

Diagnosing endometrial hyperplasia: why is it so difficult to agree?

Allison KH, Reed SD, Voigt LF, Jordan CD, Newton KM, Garcia RL.

Am J Surg Pathol. 2008 May;32(5):691-8. doi: 10.1097/PAS.0b013e318159a2a0.

13.

Relationship between menopausal hormone therapy and risk of ductal, lobular, and ductal-lobular breast carcinomas.

Li CI, Malone KE, Porter PL, Lawton TJ, Voigt LF, Cushing-Haugen KL, Lin MG, Yuan X, Daling JR.

Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):43-50. doi: 10.1158/1055-9965.EPI-07-0558. Erratum in: Cancer Epidemiol Biomarkers Prev. 2009 Oct;18(10):2803.

14.

Diabetes and endometrial cancer: an evaluation of the modifying effects of other known risk factors.

Saltzman BS, Doherty JA, Hill DA, Beresford SA, Voigt LF, Chen C, Weiss NS.

Am J Epidemiol. 2008 Mar 1;167(5):607-14. Epub 2007 Dec 10.

PMID:
18071194
15.

Long-term use of postmenopausal estrogen and progestin hormone therapies and the risk of endometrial cancer.

Doherty JA, Cushing-Haugen KL, Saltzman BS, Voigt LF, Hill DA, Beresford SA, Chen C, Weiss NS.

Am J Obstet Gynecol. 2007 Aug;197(2):139.e1-7.

PMID:
17689625
16.

Endometrial cancer risk in estrogen users after switching to estrogen-progestin therapy.

Chubak J, Doherty JA, Cushing-Haugen KL, Voigt LF, Saltzman BS, Hill DA, Beresford SA, Weiss NS.

Cancer Causes Control. 2007 Nov;18(9):1001-7. Epub 2007 Jul 25.

PMID:
17653829
17.

Ovarian cysts and breast cancer: results from the Women's Contraceptive and Reproductive Experiences Study.

Knight JA, Lesosky M, Blackmore KM, Voigt LF, Holt VL, Bernstein L, Marchbanks PA, Burkman RT, Daling JR, Whittemore AS.

Breast Cancer Res Treat. 2008 May;109(1):157-64. Epub 2007 Jul 7.

PMID:
17616808
18.
19.

Risk factors for the incidence of endometrial cancer according to the aggressiveness of disease.

Weiss JM, Saltzman BS, Doherty JA, Voigt LF, Chen C, Beresford SA, Hill DA, Weiss NS.

Am J Epidemiol. 2006 Jul 1;164(1):56-62. Epub 2006 May 4.

PMID:
16675538
20.

Interindividual variation in nucleotide excision repair genes and risk of endometrial cancer.

Weiss JM, Weiss NS, Ulrich CM, Doherty JA, Voigt LF, Chen C.

Cancer Epidemiol Biomarkers Prev. 2005 Nov;14(11 Pt 1):2524-30. Erratum in: Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):261.

21.
22.

Genetic factors in catechol estrogen metabolism in relation to the risk of endometrial cancer.

Doherty JA, Weiss NS, Freeman RJ, Dightman DA, Thornton PJ, Houck JR, Voigt LF, Rossing MA, Schwartz SM, Chen C.

Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):357-66.

23.

Re: "studies with low response proportions may be less biased than studies with high response proportions".

Voigt LF, Boudreau DM, Weiss NS, Malone KE, Li CI, Daling JR.

Am J Epidemiol. 2005 Feb 15;161(4):401-2; author reply 402-3. No abstract available.

PMID:
15692084
24.

Dose of progestin in postmenopausal-combined hormone therapy and risk of endometrial cancer.

Reed SD, Voigt LF, Beresford SA, Hill DA, Doherty JA, Weiss NS.

Am J Obstet Gynecol. 2004 Oct;191(4):1146-51.

PMID:
15507934
25.

Combined effect of oral contraceptive use and hormone replacement therapy on breast cancer risk in postmenopausal women.

Norman SA, Berlin JA, Weber AL, Strom BL, Daling JR, Weiss LK, Marchbanks PA, Bernstein L, Voigt LF, McDonald JA, Ursin G, Liff JM, Burkman RT, Malone KE, Simon MS, Folger SG, Deapen D, Wingo PA, Spirtas R.

Cancer Causes Control. 2003 Dec;14(10):933-43.

PMID:
14750532
26.

Association of regimens of hormone replacement therapy to prognostic factors among women diagnosed with breast cancer aged 50-64 years.

Daling JR, Malone KE, Doody DR, Voigt LF, Bernstein L, Marchbanks PA, Coates RJ, Norman SA, Weiss LK, Ursin G, Burkman RT, Deapen D, Folger SG, McDonald JA, Simon MS, Strom BL, Spirtas R.

Cancer Epidemiol Biomarkers Prev. 2003 Nov;12(11 Pt 1):1175-81.

27.

Characteristics of telephone survey respondents according to willingness to participate.

Voigt LF, Koepsell TD, Daling JR.

Am J Epidemiol. 2003 Jan 1;157(1):66-73.

PMID:
12505892
28.

Hormone replacement therapy regimens and breast cancer risk(1).

Weiss LK, Burkman RT, Cushing-Haugen KL, Voigt LF, Simon MS, Daling JR, Norman SA, Bernstein L, Ursin G, Marchbanks PA, Strom BL, Berlin JA, Weber AL, Doody DR, Wingo PA, McDonald JA, Malone KE, Folger SG, Spirtas R.

Obstet Gynecol. 2002 Dec;100(6):1148-58.

PMID:
12468157
29.

Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma.

Daling JR, Malone KE, Doody DR, Voigt LF, Bernstein L, Coates RJ, Marchbanks PA, Norman SA, Weiss LK, Ursin G, Berlin JA, Burkman RT, Deapen D, Folger SG, McDonald JA, Simon MS, Strom BL, Wingo PA, Spirtas R.

Cancer. 2002 Dec 15;95(12):2455-64.

30.

Racial variation in the incidence of squamous cell carcinoma of the bladder in the United States.

Porter MP, Voigt LF, Penson DF, Weiss NS.

J Urol. 2002 Nov;168(5):1960-3.

PMID:
12394685
31.

Reporting participation in case-control studies.

Olson SH, Voigt LF, Begg CB, Weiss NS.

Epidemiology. 2002 Mar;13(2):123-6.

PMID:
11880750
32.

Recreational physical activity and risk of papillary thyroid cancer (United States).

Rossing MA, Remler R, Voigt LF, Wicklund KG, Daling JR.

Cancer Causes Control. 2001 Dec;12(10):881-5.

PMID:
11808706
33.

Risk factors for synchronous primary endometrial and ovarian cancers.

Herrinton LJ, Voigt LF, Weiss NS, Beresford SA, Wingo PA.

Ann Epidemiol. 2001 Nov;11(8):529-33.

PMID:
11709271
34.

Recreational physical activity and endometrial cancer risk.

Littman AJ, Voigt LF, Beresford SA, Weiss NS.

Am J Epidemiol. 2001 Nov 15;154(10):924-33.

PMID:
11700247
35.

Continuous combined hormone replacement therapy and risk of endometrial cancer.

Hill DA, Weiss NS, Beresford SA, Voigt LF, Daling JR, Stanford JL, Self S.

Am J Obstet Gynecol. 2000 Dec;183(6):1456-61.

PMID:
11120510
36.

Multiple primary breast and thyroid cancers: role of age at diagnosis and cancer treatments (United States).

Li CI, Rossing MA, Voigt LF, Daling JR.

Cancer Causes Control. 2000 Oct;11(9):805-11.

PMID:
11075869
37.

Reproductive factors and risk of papillary thyroid cancer in women.

Rossing MA, Voigt LF, Wicklund KG, Daling JR.

Am J Epidemiol. 2000 Apr 15;151(8):765-72.

PMID:
10965973
38.

Cimetidine use and risk of prostate and breast cancer.

Rossing MA, Scholes D, Cushing-Haugen KL, Voigt LF.

Cancer Epidemiol Biomarkers Prev. 2000 Mar;9(3):319-23.

39.

Hair product use and the risk of breast cancer in young women.

Cook LS, Malone KE, Daling JR, Voigt LF, Weiss NS.

Cancer Causes Control. 1999 Dec;10(6):551-9.

PMID:
10616824
40.

Risk of papillary thyroid cancer in women in relation to smoking and alcohol consumption.

Rossing MA, Cushing KL, Voigt LF, Wicklund KG, Daling JR.

Epidemiology. 2000 Jan;11(1):49-54.

PMID:
10615843
41.

The additional risk of endometrial cancer associated with unopposed estrogen use in women with other risk factors.

Shields TS, Weiss NS, Voigt LF, Beresford SA.

Epidemiology. 1999 Nov;10(6):733-8.

PMID:
10535788
42.

Relation between obesity and breast cancer in young women.

Peacock SL, White E, Daling JR, Voigt LF, Malone KE.

Am J Epidemiol. 1999 Feb 15;149(4):339-46. Erratum in: Am J Epidemiol 2000 Apr 1;151(7):737.

PMID:
10025476
43.

Characteristics of women who use perineal powders.

Rosenblatt KA, Mathews WA, Daling JR, Voigt LF, Malone K.

Obstet Gynecol. 1998 Nov;92(5):753-6.

PMID:
9794663
44.

Prevalence and correlates of recreational physical activity in women aged 50-64 years.

McTiernan A, Stanford JL, Daling JR, Voigt LF.

Menopause. 1998 Summer;5(2):95-101.

PMID:
9689203
45.

Use of exogenous hormones hormones and risk of papillary thyroid cancer (Washington, United States).

Rossing MA, Voigt LF, Wicklund KG, Williams M, Daling JR.

Cancer Causes Control. 1998 May;9(3):341-9.

PMID:
9684714
46.

Risk of endometrial cancer in relation to use of low-dose, unopposed estrogens.

Cushing KL, Weiss NS, Voigt LF, McKnight B, Beresford SA.

Obstet Gynecol. 1998 Jan;91(1):35-9.

PMID:
9464717
47.

Re: estrogen-progestin replacement therapy and endometrial cancer.

McKnight B, Voigt LF, Beresford SA, Weiss NS.

J Natl Cancer Inst. 1998 Jan 21;90(2):164-6. No abstract available.

PMID:
9450582
48.

Menopausal hormone use and endometrial cancer, by tumor grade and invasion.

Shapiro JA, Weiss NS, Beresford SA, Voigt LF.

Epidemiology. 1998 Jan;9(1):99-101.

PMID:
9430277
49.

Characteristics of women with and without breast augmentation.

Cook LS, Daling JR, Voigt LF, deHart MP, Malone KE, Stanford JL, Weiss NS, Brinton LA, Gammon MD, Brogan D.

JAMA. 1997 May 28;277(20):1612-7.

PMID:
9168291
50.

Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women.

Beresford SA, Weiss NS, Voigt LF, McKnight B.

Lancet. 1997 Feb 15;349(9050):458-61.

PMID:
9040575

Supplemental Content

Loading ...
Support Center